ArticleClinical pharmacology and therapeutics2011
Pharmacogenomics: application to the management of cardiovascular disease.
Article in Clinical pharmacology and therapeutics, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- CYP2C9 and VKORC1 polymorphisms influence warfarin dose variability in patients on long-term anticoagulation.European journal of clinical pharmacology · 2013Trial
- CYP2C gene polymorphisms in North African populations.Molecular biology reports · 2024Article
- Variation in Actionable Pharmacogenetic Markers in Natives and Mestizos From Mexico.Frontiers in pharmacology · 2019Article
- Association BetweenFrontiers in pharmacology · 2018Article
- Incorporating Pharmacogenomics into Health Information Technology, Electronic Health Record and Decision Support System: An Overview.Journal of medical systems · 2017Review
- Pharmacogenetics of Drug-Induced QT Interval Prolongation: An Update.Drug safety · 2015Review
- Opinions, hopes and concerns regarding pharmacogenomics: a comparison of healthy individuals, heart failure patients and heart transplant recipients.The pharmacogenomics journal · 2015Article
- Personalized antiplatelet and anticoagulation therapy: applications and significance of pharmacogenomics.Pharmacogenomics and personalized medicine · 2015Review
- G protein-coupled receptor kinase 5 gene polymorphisms are associated with postoperative atrial fibrillation after coronary artery bypass grafting in patients receiving β-blockers.Circulation. Cardiovascular genetics · 2014Article
- Pharmacogenetics of heart failure.Current opinion in cardiology · 2014Review
- The genetics of pro-arrhythmic adverse drug reactions.British journal of clinical pharmacology · 2014Review
- Pathogenesis of coronary artery disease: focus on genetic risk factors and identification of genetic variants.The application of clinical genetics · 2014Review
- Electronic health record design and implementation for pharmacogenomics: a local perspective.Genetics in medicine : official journal of the American College of Medical Genetics · 2013Article
- Pharmacogenetics and cardiovascular disease--implications for personalized medicine.Pharmacological reviews · 2013Review
- VKORC1 Asp36Tyr geographic distribution and its impact on warfarin dose requirements in Egyptians.Thrombosis and haemostasis · 2013Article
- Genetics of congenital and drug-induced long QT syndromes: current evidence and future research perspectives.Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing · 2013Review
- Clopidogrel and warfarin pharmacogenetic tests: what is the evidence for use in clinical practice?Current opinion in cardiology · 2013Review
- The Making of a CYP3A Biomarker Panel for Guiding Drug Therapy.Journal of personalized medicine · 2012Article
- Transporter pharmacogenetics: transporter polymorphisms affect normal physiology, diseases, and pharmacotherapy.Discovery medicine · 2012Review
Corrections and comments
- Comment on
Authors and funding
6 authors.
Funding
Abstract
The past decade has seen substantial advances in cardiovascular pharmacogenomics. Genetic determinants of response to clopidogrel and warfarin have been defined, resulting in changes to the product labels for these drugs that suggest the use of genetic information as a guide for therapy. Genetic tests are available, as are guidelines for incorporation of genetic information into patient-care decisions. These guidelines and the literature supporting them are reviewed herein. Significant advances have also been made in the pharmacogenomics of statin-induced myopathy and the response to β-blockers in heart failure, although the clinical applications of these findings are less clear. Other areas hold promise, including the pharmacogenomics of antihypertensive drugs, aspirin, and drug-induced long-QT syndrome (diLQTS). The potential value of pharmacogenomics in the discovery and development of new drugs is also described. In summary, pharmacogenomics has current applications in the management of cardiovascular disease, with clinically relevant data continuing to mount.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.